TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8113062

Group type: EXPERIMENTAL
Intervention: CATCH program implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CATCH process evaluation system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CATCH process measures and data collection protocols
Number of subjects: 0
Study: 3072356

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ketoprofen 300 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg plus Codeine 60 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 30820571

Group type: EXPERIMENTAL
Intervention: Tweets with warnings
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Tweets featuring e‐cigarette products
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Tweets featuring e‐cigarette use
Number of subjects: 994

Group type: COMPARATOR
Intervention: Tweets without warnings
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Warnings
Number of subjects: 994
Study: 30265306

Group type: EXPERIMENTAL
Intervention: 200 mg progesterone vaginal pessaries bid
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 400 mg progesterone vaginal pessaries bid
Number of subjects: 147

Group type: COMPARATOR
Intervention: 90 mg progesterone vaginal gel od
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 100 mg progesterone vaginal pessaries bid
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 400 mg progesterone vaginal pessaries od
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo vaginal pessaries bid
Number of subjects: 147
Study: 28699555

Group type: EXPERIMENTAL
Intervention: Intervention Clusters (IC)
Number of subjects: 11933

Group type: COMPARATOR
Intervention: Control Clusters (CC)
Number of subjects: 11933
Study: 25769395

Group type: EXPERIMENTAL
Intervention: SG1 (Urethral catheter removal at 48 hours post-operatively)
Number of subjects: 44

Group type: COMPARATOR
Intervention: SG2 (Urethral catheter removed following cessation of epidural analgesia)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: SG1
Number of subjects: 44

Group type: COMPARATOR
Intervention: SG2
Number of subjects: 44
Study: 23552821

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET, n = 15)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Health Education without Training (EA, n = 14)
Number of subjects: 39
Study: 21199812

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: MI with feedback (MIFB)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Feedback (FB)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Assessment only (AO)
Number of subjects: 229
Study: 18040702

Group type: EXPERIMENTAL
Intervention: Surgical stabilization within 8 hours of spinal cord injury (Group I, n=12)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Surgical stabilization between 3 and 15 days after injury (Group II, n=15)
Number of subjects: 27
Study: 16464703

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy for Adolescents (CBGT‐A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Social Effectiveness Therapy for Adolescents‐‐Spanish version (SET‐Asv)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intervención en Adolescentes con Fobia Social‐‐Treatment for Adolescents with Social Phobia (IAFS)
Number of subjects: 23
Study: 14742328

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with bupivacaine
Number of subjects: 33
Study: 11704914

Group type: EXPERIMENTAL
Intervention: Gd-EOB-DTPA (3, 6, 12.5, 25, and 50 micromol/kg b. w. as a bolus injection)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Gd-DTPA (0.1 mmol/kg b. w. as a bolus injection)
Number of subjects: 61
Study: 9390615

Group type: EXPERIMENTAL
Intervention: Isoflurane (IH group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol (IV group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study: 8184127

Group type: EXPERIMENTAL
Intervention: Skill training
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Traditional stimulation approach
Number of subjects: 63

Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 63
Study: 3579008

Group type: EXPERIMENTAL
Intervention: Breathing 11% O2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Breathing 100% O2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patients with cutaneous spider nevi
Number of subjects: 15

Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 15
Study: 29346040

Group type: EXPERIMENTAL
Intervention: Bevacizumab maintenance
Number of subjects: 491

Group type: COMPARATOR
Intervention: No treatment (observation)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Bevacizumab maintenance (per-protocol population)
Number of subjects: 491

Group type: COMPARATOR
Intervention: No treatment (observation) (per-protocol population)
Number of subjects: 491
Study: 27720942

Group type: EXPERIMENTAL
Intervention: Hematoporphyrin PDT and stent placement (PDT+stent group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Stent-only (stent group)
Number of subjects: 39
Study: 25033137

Group type: EXPERIMENTAL
Intervention: Peer-delivered HIV information
Number of subjects: 112

Group type: COMPARATOR
Intervention: General health information
Number of subjects: 112
Study: 23553347

Group type: EXPERIMENTAL
Intervention: Thrive with Me (TWM) intervention
Number of subjects: 124
Study: 20502739

Group type: EXPERIMENTAL
Intervention: Sulphurous thermal water inhalations
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiological solution
Number of subjects: 80
Study: 18939349

Group type: EXPERIMENTAL
Intervention: Multiburst mode
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Shortpulse mode
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Whitestar technology
Number of subjects: 101
Study: 16364549

Group type: COMPARATOR
Intervention: Placebo (fake analgesic cream)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No placebo condition
Number of subjects: 19
Study: 14505118

Group type: EXPERIMENTAL
Intervention: Behavioral graded activity (BGA) program
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 105
Study: 11707882

Group type: EXPERIMENTAL
Intervention: Toddler-parent psychotherapy (TPP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Non-depressed control group
Number of subjects: 63
Study: 8680609

Group type: EXPERIMENTAL
Intervention: Insulin resistance assessed using the frequently sampled intravenous glucose tolerance test with minimal model analysis
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Intimal-medial carotid artery wall thickness measured using B-mode ultrasonography
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Prevalent CVD assessed by questionnaire and resting electrocardiography
Number of subjects: 1600
Study: 2615196

Group type: EXPERIMENTAL
Intervention: Chronicity Index (CI)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Activity Index (AI)
Number of subjects: 84
Study: 795261

Group type: EXPERIMENTAL
Intervention: Sucrose (S 35)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Fructose (F 38)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Xylitol (X 52)
Number of subjects: 125
Study: 31811378

Group type: EXPERIMENTAL
Intervention: 3D visualisations
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 3D-printed model
Number of subjects: 91

Group type: COMPARATOR
Intervention: Photographs
Number of subjects: 91
Study: 30604599

Group type: EXPERIMENTAL
Intervention: Metformin, Sitagliptin, and Acarbose (Met+Sita+Acarb)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Metformin and Sitagliptin (Met+Sita)
Number of subjects: 165
Study: 28712940

Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 140

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 140
Study: 25311708

Group type: EXPERIMENTAL
Intervention: Conformational positioner
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard mattress
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Surgical subjects
Number of subjects: 25
Study: 23386424

Group type: EXPERIMENTAL
Intervention: Acute normobaric hypoxia at rest (PHE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acute normobaric hypoxia during exercise (AHE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 20
Study: 22545117

Group type: EXPERIMENTAL
Intervention: Training traditional birth attendants (TBAs)
Number of subjects: 0
Study: 19364991

Group type: EXPERIMENTAL
Intervention: Low-saturated-fat, low-cholesterol diet
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1062
Study: 17516967

Group type: EXPERIMENTAL
Intervention: Prolongation of pregnancy in early‐onset hypertensive disorders
Number of subjects: 216
Study: 15382598

Group type: EXPERIMENTAL
Intervention: Listening to music preoperatively and postoperatively
Number of subjects: 0
Study: 11266263

Group type: EXPERIMENTAL
Intervention: Preoperative serum concentrations of hepatocyte growth factor (HGF)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Preoperative nutritional state
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Postoperative IL‐6 response
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Development of infective complications
Number of subjects: 82
Study: 10068082

Group type: EXPERIMENTAL
Intervention: S-phase fraction
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Tumor size
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Patient age at surgery
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Progesterone receptor (PgR) status
Number of subjects: 4000
Study: 7736480

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic chronic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring
Number of subjects: 0
Study: 3437508

Group type: EXPERIMENTAL
Intervention: Trapidil (400 mg daily on days 1 to 8, 200 mg on day 9)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31014775

Group type: EXPERIMENTAL
Intervention: (−)-epicatechin 1 mg/kg BW
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: (−)-epicatechin 0.5 mg/kg BW
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: (−)-epicatechin 0.1 mg/kg BW
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water only (control)
Number of subjects: 20
Study: 29679981

Group type: EXPERIMENTAL
Intervention: Red plates
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Black plates
Number of subjects: 54

Group type: COMPARATOR
Intervention: White plates
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Comparison between red and black plates
Number of subjects: 54
Study: 26422126

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol (0.15 mg/kg)
Number of subjects: 273
Study: 23962422

Group type: EXPERIMENTAL
Intervention: Interactive software for weight self-monitoring (Intervention Group)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 281
Study: 22649299

Group type: EXPERIMENTAL
Intervention: Authentic acupuncture
Number of subjects: 196

Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 196
Study: 21244805

Group type: EXPERIMENTAL
Intervention: Percutaneous tendo-achilles lengthening (TAL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Open tendo-achilles lengthening (TAL)
Number of subjects: 18
Study: 19127002

Group type: EXPERIMENTAL
Intervention: Use of electronic devices (PDAs and smartphones)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors influencing success
Number of subjects: 0
Study: 19403495

Group type: EXPERIMENTAL
Intervention: Longer leaflet without verbal explanation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Shorter leaflet
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Verbal explanation (regardless of documentation style)
Number of subjects: 41

Group type: COMPARATOR
Intervention: All groups (irrespective of documentation style)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Documentation style (longer vs shorter)
Number of subjects: 41
Study: 14967213

Group type: EXPERIMENTAL
Intervention: Visual training associated with reading
Number of subjects: 0
Study: 11318063

Group type: EXPERIMENTAL
Intervention: Spatial cues and attention in a Simon task
Number of subjects: 0
Study: 9161744

Group type: EXPERIMENTAL
Intervention: Atracurium (0.05 mg.kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg.kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atracurium and Lidocaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 80
Study: 8424378

Group type: EXPERIMENTAL
Intervention: PPA (75 mg osmotic release oral system (OROS)‐PPA/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PPA
Number of subjects: 24
Study: 3122275

Group type: EXPERIMENTAL
Intervention: Misoprostol (400 mcg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31741957

Group type: EXPERIMENTAL
Intervention: Cold Dissection Technique (CDT)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Bipolar Electrocautery Technique (BET)
Number of subjects: 534
Study: 27742998

Group type: EXPERIMENTAL
Intervention: EP217609 (4, 8, 12 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Avidin (30-min intravenous infusion)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Avidin (2:1 and 3:1 molar ratios)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: EP217609 and Avidin
Number of subjects: 36
Study: 26399451

Group type: EXPERIMENTAL
Intervention: Vitamin D3 16800 IU orally once a week for 1 year
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo orally once a week for 1 year
Number of subjects: 240
Study: 25108749

Group type: EXPERIMENTAL
Intervention: Classic Massage (CM)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Connective Tissue Massage (CTM)
Number of subjects: 45
Study: 21969418

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 342

Group type: COMPARATOR
Intervention: Waiting List (Control)
Number of subjects: 342
Study: 19687579

Group type: EXPERIMENTAL
Intervention: cilnidipine 5-10 mg/day
Number of subjects: 78

Group type: COMPARATOR
Intervention: amlodipine 5-7.5 mg/day
Number of subjects: 78
Study: 17684620

Group type: EXPERIMENTAL
Intervention: L-arginine (7 grams per day for seven days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 15110198

Group type: EXPERIMENTAL
Intervention: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/hour infusion during the procedure)
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Heparin (70 U/kg initial bolus)
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1056
Study: 11574500

Group type: EXPERIMENTAL
Intervention: Fresh spermatozoa (group A)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Frozen-thawed spermatozoa (group B)
Number of subjects: 240
Study: 9132880

Group type: EXPERIMENTAL
Intervention: Health related quality of life measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac Surgery Reporting System registry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient Outcome Research Teams (PORTs) projects
Number of subjects: 0
Study: 7951291

Group type: COMPARATOR
Intervention: Static muscle stretch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ballistic muscle stretch
Number of subjects: 0
Study: 3608733

Group type: EXPERIMENTAL
Intervention: Arbacet 25 micrograms four times daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 28779544

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Alfentanil (A)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Lidocaine (C)
Number of subjects: 162
Study: 27367766

Group type: EXPERIMENTAL
Intervention: Standardized rehabilitation therapy (SRT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study: 25176376

Group type: EXPERIMENTAL
Intervention: 22.63 mg/kg emulsified isoflurane
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 38.26 mg/kg emulsified isoflurane
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 49.73 mg/kg emulsified isoflurane
Number of subjects: 3
Study: 21636188

Group type: EXPERIMENTAL
Intervention: Active manuka honey 20 ml 4 times daily for 6 weeks
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (golden syrup) 20 ml 4 times daily for 6 weeks
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Active manuka honey and Placebo (golden syrup)
Number of subjects: 131
Study: 21029641

Group type: EXPERIMENTAL
Intervention: Shenfu injection (SF injection) administered by peripheral intravenous infusion at initially 0.2 ml/kg and then 0.8 ml (kg/h) until the end of operations
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline (Group N) administered similarly
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Shenfu injection (SF injection)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline (Group N)
Number of subjects: 24
Study: 18684185

Group type: EXPERIMENTAL
Intervention: Single-dose lubiprostone (24 microg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 15516362

Group type: EXPERIMENTAL
Intervention: Infants with RDS
Number of subjects: 52
Study: 12322842

Group type: EXPERIMENTAL
Intervention: Songkla uterine manipulator (SUM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hulka controlling tenaculum
Number of subjects: 40
Study: 10415055

Group type: EXPERIMENTAL
Intervention: anti-TNF-alpha therapy
Number of subjects: 0
Study: 7594063

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (n = 99)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo (n = 115)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (2 g/day)
Number of subjects: 245
Study: 2255726

Group type: EXPERIMENTAL
Intervention: 1.5 g POT II in a high-protein soup vehicle (70 kcal)
Number of subjects: 11

Group type: COMPARATOR
Intervention: soup vehicle alone
Number of subjects: 11

Group type: COMPARATOR
Intervention: no-soup control
Number of subjects: 11
Study: 6996625

Group type: EXPERIMENTAL
Intervention: Clindamycin combined with tobramycin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Metronidazole combined with tobramycin
Number of subjects: 57
Study: 31651314

Group type: EXPERIMENTAL
Intervention: PACE Steps to Success programme (educational and development intervention)
Number of subjects: 3638

Group type: EXPERIMENTAL
Intervention: Training provided to country trainers
Number of subjects: 3638

Group type: EXPERIMENTAL
Intervention: Framework for cross-cultural adaptation
Number of subjects: 3638
Study: 28107852

Group type: EXPERIMENTAL
Intervention: Topical chamomile oil
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 25332071

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC) followed by azathioprine (AZA)
Number of subjects: 197
Study: 24167595

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage
Number of subjects: 203

Group type: COMPARATOR
Intervention: Sugar-free beverage
Number of subjects: 203
Study: 21116816

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg every 6 hours for 3 days
Number of subjects: 793

Group type: COMPARATOR
Intervention: Fluvastatin 80 mg single dose prior to ZOL infusion
Number of subjects: 793

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study: 19508669

Group type: EXPERIMENTAL
Intervention: Platelets stored for 1-5 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Platelets stored for 6-7 days
Number of subjects: 60
Study: 17786991

Group type: EXPERIMENTAL
Intervention: High-resistance heat and moisture exchangers (HMEs)
Number of subjects: 20
Study: 15291677

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Olanzapine-Fluoxetine Combination (OFC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (Fluoxetine)
Number of subjects: 45
Study: 11167284

Group type: EXPERIMENTAL
Intervention: SF6 20%
Number of subjects: 33

Group type: COMPARATOR
Intervention: BSS
Number of subjects: 33
Study: 9808215

Group type: EXPERIMENTAL
Intervention: School-based aerobic exercise program (15-min walk and 20-min aerobic dance, 3 times a week for 29.6 weeks)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: School-based aerobic exercise program
Number of subjects: 292
Study: 7697842

Group type: EXPERIMENTAL
Intervention: Successful balloon dilatation of coronary occlusions
Number of subjects: 2950

Group type: COMPARATOR
Intervention: Successful balloon dilatation of total occlusions
Number of subjects: 2950
Study: 2515306

Group type: EXPERIMENTAL
Intervention: IVN for 3 days (0.18 gN/kg/day as amino acid; 30 kcal/kg/day as glucose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IVN for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: No IVN
Number of subjects: 30
Study: 321704

Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin
Number of subjects: 235

Group type: COMPARATOR
Intervention: Immune serum globulin (control)
Number of subjects: 235
Study: 30341143

Group type: EXPERIMENTAL
Intervention: Combined steroid and mycophenolate mofetil (MMF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard steroid treatment
Number of subjects: 120
Study: 27741200

Group type: EXPERIMENTAL
Intervention: Psychotherapy with somatosensory stimulation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 67